Home › Myelodysplastic Syndromes › NCT06692894
Defining Inflammatory Markers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Defining Inflammatory Biomarkers of Cardiovascular Disease in Patients With Myelodysplastic Syndromes
Who can join
Ages 18 and older · All sexes
Full eligibility criteria
Inclusion Criteria: * Age ≥18 years * Histologically confirmed diagnosis of MDS by bone marrow biopsy morphology, using the 2022 World Health Organization (WHO) classification for myeloid neoplasms * Eastern Cooperative Oncology Group (ECOG) performance status ≤3 * Expected survival of at least 6 months * Ability to provide consent Exclusion Criteria: * Cases meeting 2022 WHO criteria of MDS with excess blasts 2 as initial diagnosis * Hematopoietic stem cell transplantation expected within 6 months
About the study
Why Is This Research Study Being Conducted?
* The study wants to find out why people with a type of blood cancer called myelodysplastic syndromes (MDS) are more likely to have heart problems like heart disease and stroke. * Researchers also want to see if certain proteins related to inflammation in the body can help predict these heart issues in MDS patients. * By understanding this better, researchers hope to find new ways to detect and manage heart disease risks in people with MDS
What is being tested
- Observational (other)
Sponsor: University of Vermont · Participants: 30 · Started: Nov 5, 2024
Contact the study team
- Diego Adrianzen Herrera, MD · Phone: (802) 656-2021
- Neil A Zakai, MD · Phone: (802) 656-2021
Official record on ClinicalTrials.gov — NCT06692894
Locations in the U.S.
| Vermont | University of Vermont, Burlington |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.